Injectable GLP-1-based therapies, including semaglutide and tirzepatide, have demonstrated substantial benefits for weight loss and cardiometabolic risk reduction ( 1 3 ), but real-world uptake has been shaped by factors such as route of administration, access, tolerability, and insurance coverage ( 4 7 )
From their beginnings as a treatment for type 2 diabetes, GLP-1 receptor agonists such as the semaglutide drugs Ozempic and Wegovy and the tirzepatide drugs Mounjaro and Zepbound have seen an explosion in use, most popularly for weight loss
You can watch by clicking this link here this link here Want More Like This
For diarrhoea related to medication, K52.9 (Noninfective gastroenteritis and colitis, unspecified) or R19.7 (Diarrhoea, unspecified) may be appropriate depending on clinical context